Gustavo A. Rosario Benitez

Array ( [id] => 11649198 [patent_doc_number] => 20170145099 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'METHOD FOR REDUCING SIDE EFFECTS OF IMMUNE CHECKPOINT CONTROL AGENT' [patent_app_type] => utility [patent_app_number] => 15/316592 [patent_app_country] => US [patent_app_date] => 2015-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 8734 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15316592 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10459541 [patent_doc_number] => 20150344556 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-03 [patent_title] => 'EXTRACELLULAR HISTONES AS BIOMARKERS FOR PROGNOSIS AND MOLECULAR TARGETS FOR THERAPY' [patent_app_type] => utility [patent_app_number] => 14/734238 [patent_app_country] => US [patent_app_date] => 2015-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 21729 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14734238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10428966 [patent_doc_number] => 20150313977 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-05 [patent_title] => 'IMMUNOGENIC FRAGMENTS OF T-CELL RECEPTOR CONSTANT DOMAINS AND PEPTIDES DERIVED THEREFROM' [patent_app_type] => utility [patent_app_number] => 14/733949 [patent_app_country] => US [patent_app_date] => 2015-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 27295 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14733949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10453396 [patent_doc_number] => 20150338411 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-26 [patent_title] => 'BIOMARKER FOR THE PREDICTION OF RESPONSIVENESS TO AN ANTI-TUMOUR NECROSIS FACTOR ALPHA (TNF) TREATMENT' [patent_app_type] => utility [patent_app_number] => 14/730497 [patent_app_country] => US [patent_app_date] => 2015-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 126 [patent_figures_cnt] => 126 [patent_no_of_words] => 9368 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14730497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10452021 [patent_doc_number] => 20150337035 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-26 [patent_title] => 'ANTIBODIES TO TNF ALPHA AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/724200 [patent_app_country] => US [patent_app_date] => 2015-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 57114 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14724200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13251235 [patent_doc_number] => 10138297 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-27 [patent_title] => Antibody neutralizers of human granulocyte macrophage colony stimulating factor [patent_app_type] => utility [patent_app_number] => 14/718923 [patent_app_country] => US [patent_app_date] => 2015-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 47 [patent_no_of_words] => 26126 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14718923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10361963 [patent_doc_number] => 20150246968 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-03 [patent_title] => 'METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/715310 [patent_app_country] => US [patent_app_date] => 2015-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 18793 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14715310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11963584 [patent_doc_number] => 20170267737 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma' [patent_app_type] => utility [patent_app_number] => 15/310727 [patent_app_country] => US [patent_app_date] => 2015-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 16185 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15310727 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10452027 [patent_doc_number] => 20150337041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-26 [patent_title] => 'METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES OR CONDITIONS' [patent_app_type] => utility [patent_app_number] => 14/701779 [patent_app_country] => US [patent_app_date] => 2015-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18302 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14701779 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10669633 [patent_doc_number] => 20160015779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-21 [patent_title] => 'IMMUNOMODULATING TUMOR NECROSIS FACTOR RECEPTOR 25 (TNFR25) AGONISTS, ANTAGONISTS, AND IMMUNOTOXINS' [patent_app_type] => utility [patent_app_number] => 14/697007 [patent_app_country] => US [patent_app_date] => 2015-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 22246 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14697007 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10340472 [patent_doc_number] => 20150225477 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-13 [patent_title] => 'Compositions for Selective Reduction of Circulating Bioactive Soluble TNF and Methods for Treating TNF-Mediated Disease' [patent_app_type] => utility [patent_app_number] => 14/695551 [patent_app_country] => US [patent_app_date] => 2015-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 10251 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14695551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10340473 [patent_doc_number] => 20150225478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-13 [patent_title] => 'Immunogenic and Prophylactic Compositions, Methods of Making Same, and Methods for Treating and Preventing TNF-Mediated Disease' [patent_app_type] => utility [patent_app_number] => 14/695807 [patent_app_country] => US [patent_app_date] => 2015-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 14269 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14695807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15915359 [patent_doc_number] => 10654908 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-19 [patent_title] => Isolated T cell receptors and methods of use therefor [patent_app_type] => utility [patent_app_number] => 15/303677 [patent_app_country] => US [patent_app_date] => 2015-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 30 [patent_no_of_words] => 27174 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15303677 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11421362 [patent_doc_number] => 20170029506 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'Immunoglobulins Binding Human Vgamma9 Vdelta2 T Cell Receptors' [patent_app_type] => utility [patent_app_number] => 15/302927 [patent_app_country] => US [patent_app_date] => 2015-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11749 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15302927 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11401749 [patent_doc_number] => 20170022287 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-26 [patent_title] => 'Immunoactivating Antigen-Binding Molecule' [patent_app_type] => utility [patent_app_number] => 15/302439 [patent_app_country] => US [patent_app_date] => 2015-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 35006 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 30 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15302439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10422832 [patent_doc_number] => 20150307842 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-29 [patent_title] => 'T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 14/676028 [patent_app_country] => US [patent_app_date] => 2015-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 14735 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14676028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12253089 [patent_doc_number] => 09925220 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-27 [patent_title] => 'Method of expanding double negative T cells' [patent_app_type] => utility [patent_app_number] => 14/674548 [patent_app_country] => US [patent_app_date] => 2015-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 7854 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14674548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11706269 [patent_doc_number] => 20170174764 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'T-CELL RECEPTOR CDR3 PEPTIDES AND ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/127023 [patent_app_country] => US [patent_app_date] => 2015-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 49782 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15127023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11690922 [patent_doc_number] => 20170166638 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'USE OF CD-64-BLOCKING AGENTS AS ENHANCER OF AN ANTI-TNF-a ANTIBODY THERAPY' [patent_app_type] => utility [patent_app_number] => 15/126690 [patent_app_country] => US [patent_app_date] => 2015-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 6555 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15126690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10700567 [patent_doc_number] => 20160046714 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'Methods for the Treatment of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies with Reduced Toxicity' [patent_app_type] => utility [patent_app_number] => 14/668036 [patent_app_country] => US [patent_app_date] => 2015-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 64172 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14668036 [rel_patent_id] =>[rel_patent_doc_number] =>)